Literature DB >> 26160876

Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG.

Roland B Walter1, Megan Othus2, Bob Löwenberg3, Gert J Ossenkoppele4, Stephen H Petersdorf5, Thomas Pabst6, Marie-Christiane Vekemans7, Frederick R Appelbaum5, Harry P Erba8, Elihu H Estey9.   

Abstract

Entities:  

Keywords:  acute myeloid leukemia; clinical trials; eligibility criteria; refractory; relapsed

Mesh：

Year:  2015        PMID： 26160876      PMCID： PMC4591777          DOI： 10.3324/haematol.2015.130013

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia.

Authors:  E Estey; S Kornblau; S Pierce; H Kantarjian; M Beran; M Keating
Journal:  Blood       Date:  1996-07-15       Impact factor: 22.113

2.  Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy.

Authors:  W Hiddemann; W R Martin; C M Sauerland; A Heinecke; T Büchner
Journal:  Leukemia       Date:  1990-03       Impact factor: 11.528

3.  Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.

Authors:  Roland B Walter; Megan Othus; Gautam Borthakur; Farhad Ravandi; Jorge E Cortes; Sherry A Pierce; Frederick R Appelbaum; Hagop A Kantarjian; Elihu H Estey
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

4.  Prognostic index for adult patients with acute myeloid leukemia in first relapse.

Authors:  Dimitri A Breems; Wim L J Van Putten; Peter C Huijgens; Gert J Ossenkoppele; Gregor E G Verhoef; Leo F Verdonck; Edo Vellenga; Georgine E De Greef; Emanuel Jacky; Johannes Van der Lelie; Marc A Boogaerts; Bob Löwenberg
Journal:  J Clin Oncol       Date:  2005-01-04       Impact factor: 44.544

5.  Response to salvage therapy and survival after relapse in acute myelogenous leukemia.

Authors:  M J Keating; H Kantarjian; T L Smith; E Estey; R Walters; B Andersson; M Beran; K B McCredie; E J Freireich
Journal:  J Clin Oncol       Date:  1989-08       Impact factor: 44.544

Review 6.  Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

Authors:  Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel A Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

Review 7.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

8.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

Authors:  Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

Review 9.  Acute myeloid leukaemia in adults.

Authors:  Felicetto Ferrara; Charles A Schiffer
Journal:  Lancet       Date:  2013-02-09       Impact factor: 79.321
  9 in total
  2 in total

1.  Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.

Authors:  Jonathan S Serody; Ivana Gojo; Joshua F Zeidner; Benjamin G Vincent; Anastasia Ivanova; Dominic Moore; Karen P McKinnon; Alec D Wilkinson; Rupkatha Mukhopadhyay; Francesco Mazziotta; Hanna A Knaus; Matthew C Foster; Catherine C Coombs; Katarzyna Jamieson; Hendrik Van Deventer; Jonathan A Webster; Gabrielle T Prince; Amy E DeZern; B Douglas Smith; Mark J Levis; Nathan D Montgomery; Leo Luznik
Journal:  Blood Cancer Discov       Date:  2021-09-10

2.  Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia.

Authors:  Geoffrey L Uy; Ibrahim Aldoss; Matthew C Foster; Peter H Sayre; Matthew J Wieduwilt; Anjali S Advani; John E Godwin; Martha L Arellano; Kendra L Sweet; Ashkan Emadi; Farhad Ravandi; Harry P Erba; Michael Byrne; Laura Michaelis; Max S Topp; Norbert Vey; Fabio Ciceri; Matteo Giovanni Carrabba; Stefania Paolini; Gerwin A Huls; Mojca Jongen-Lavrencic; Martin Wermke; Patrice Chevallier; Emmanuel Gyan; Christian Récher; Patrick J Stiff; Kristen M Pettit; Bob Löwenberg; Sarah E Church; Erica Anderson; Jayakumar Vadakekolathu; Marianne Santaguida; Michael P Rettig; John Muth; Teia Curtis; Erin Fehr; Kuo Guo; Jian Zhao; Ouiam Bakkacha; Kenneth Jacobs; Kathy Tran; Patrick Kaminker; Maya Kostova; Ezio Bonvini; Roland B Walter; Jan K Davidson-Moncada; Sergio Rutella; John F DiPersio
Journal:  Blood       Date:  2021-02-11       Impact factor: 25.476
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.